ArticleCrohn's & colitis 3602026
Urinary biomarkers of urolithiasis risk in Crohn's disease: hyperoxaluria, hypocitraturia, and hypomagnesuria in patients with and without ileocolic resection.
Article in Crohn's & colitis 360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aims: Patients with Crohn's disease (CD) are at an increased risk of urolithiasis, particularly after ileocolic (IC) resection. This study aimed to investigate the prevalence of hyperoxaluria, hypocitraturia, and hypomagnesuria in CD patients with and without IC resection, compared to healthy controls. Methods: This cross-sectional study included three groups: CD patients who had undergone IC resection (group 1), CD patients with IC involvement but without active inflammation and without resection (group 2), and healthy controls (group 3). Each participant collected a 24-hour urine sample for analysis of oxalate, citrate, and magnesium excretion. Results: A total of 107 participants were enrolled (34 in group 1, 42 in group 2, and 31 in group 3). The prevalence of hyperoxaluria was 26.5% in group 1, 35.7% in group 2, and 29.0% in group 3, with no significant differences between groups ( Conclusion: While hyperoxaluria prevalence was similar across groups, hypocitraturia and hypomagnesuria were more frequent in CD patients, particularly those with IC resection. Monitoring these biomarkers may help identify at-risk individuals and guide prevention of urolithiasis in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.